MARCHESELLI, Raffaella
 Distribuzione geografica
Continente #
NA - Nord America 5.434
EU - Europa 2.657
AS - Asia 1.783
SA - Sud America 253
AF - Africa 61
OC - Oceania 14
Continente sconosciuto - Info sul continente non disponibili 4
Totale 10.206
Nazione #
US - Stati Uniti d'America 5.354
GB - Regno Unito 1.292
CN - Cina 635
SG - Singapore 526
IT - Italia 336
HK - Hong Kong 265
DE - Germania 234
SE - Svezia 222
BR - Brasile 192
RU - Federazione Russa 109
FR - Francia 106
UA - Ucraina 103
FI - Finlandia 87
VN - Vietnam 76
TR - Turchia 66
IN - India 48
CA - Canada 45
BG - Bulgaria 43
ID - Indonesia 39
MA - Marocco 38
KR - Corea 34
AR - Argentina 26
BE - Belgio 17
MX - Messico 15
PL - Polonia 15
ES - Italia 14
IE - Irlanda 13
AU - Australia 12
CH - Svizzera 12
ZA - Sudafrica 12
BD - Bangladesh 11
NL - Olanda 11
CZ - Repubblica Ceca 10
EC - Ecuador 10
IR - Iran 9
LT - Lituania 8
MY - Malesia 8
AE - Emirati Arabi Uniti 7
AT - Austria 7
CL - Cile 7
CO - Colombia 7
IQ - Iraq 7
JP - Giappone 7
PK - Pakistan 6
UZ - Uzbekistan 6
AZ - Azerbaigian 5
BZ - Belize 5
HU - Ungheria 5
KZ - Kazakistan 5
PH - Filippine 5
VE - Venezuela 5
DO - Repubblica Dominicana 4
EU - Europa 3
GP - Guadalupe 3
JM - Giamaica 3
KE - Kenya 3
KG - Kirghizistan 3
NO - Norvegia 3
BO - Bolivia 2
CR - Costa Rica 2
DK - Danimarca 2
IL - Israele 2
JO - Giordania 2
LB - Libano 2
NZ - Nuova Zelanda 2
PT - Portogallo 2
PY - Paraguay 2
RO - Romania 2
SA - Arabia Saudita 2
A2 - ???statistics.table.value.countryCode.A2??? 1
AD - Andorra 1
AM - Armenia 1
AO - Angola 1
BF - Burkina Faso 1
BH - Bahrain 1
CY - Cipro 1
EG - Egitto 1
GA - Gabon 1
GH - Ghana 1
GR - Grecia 1
KH - Cambogia 1
LU - Lussemburgo 1
MM - Myanmar 1
MU - Mauritius 1
PA - Panama 1
PE - Perù 1
RS - Serbia 1
SV - El Salvador 1
TJ - Tagikistan 1
TT - Trinidad e Tobago 1
TW - Taiwan 1
TZ - Tanzania 1
UG - Uganda 1
UY - Uruguay 1
Totale 10.206
Città #
Southend 1.070
Fairfield 592
Ashburn 528
Santa Clara 492
Woodbridge 458
Singapore 338
Houston 275
Chandler 269
Hong Kong 265
Seattle 245
Wilmington 220
Ann Arbor 206
Cambridge 205
Jacksonville 203
Beijing 171
Dearborn 163
Nyköping 162
Hefei 137
London 112
New York 102
Modena 94
Chicago 73
Los Angeles 72
San Diego 57
Frankfurt am Main 56
Princeton 42
Shanghai 42
Sofia 42
Munich 39
Eugene 38
Helsinki 38
Council Bluffs 37
Moscow 35
Salt Lake City 34
Casablanca 32
Seoul 31
Milan 30
Izmir 29
The Dalles 27
Bremen 26
Bologna 24
Buffalo 24
Jakarta 23
Ho Chi Minh City 22
San Jose 21
Columbus 20
Elk Grove Village 19
São Paulo 18
Brussels 17
Redwood City 17
Falls Church 16
Montreal 16
Phoenix 16
Turku 15
Hanoi 14
Boardman 13
Dallas 13
Denver 13
Des Moines 13
Dublin 13
Nanjing 13
Rome 13
Warsaw 13
Fremont 12
New Delhi 12
Tampa 12
Guangzhou 11
Brooklyn 10
Dong Ket 10
Poplar 10
Kunming 9
Norwalk 9
Rho 9
Boston 8
Indiana 8
Ottawa 8
San Giuliano Milanese 8
San Mateo 8
Stockholm 8
Buenos Aires 7
Carpi 7
Gurugram 7
Nuremberg 7
Orem 7
Paris 7
Sterling 7
Tokyo 7
Toronto 7
Turin 7
Uppsala 7
Atlanta 6
Dongguan 6
Hebei 6
Johannesburg 6
Manchester 6
Verona 6
Zhengzhou 6
Augusta 5
Baku 5
Belize City 5
Totale 7.759
Nome #
Therapy-related myeloid neoplasm in non-hodgkin lymphoma survivors. 583
Absolute monocyte count at diagnosis could improve the prognostic role of early FDG-PET in classical Hodgkin lymphoma patients 455
A Multicenter Phase II Study of Twice-Weekly Bortezomib plus Rituximab in Patients with Relapsed Follicular Lymphoma: Long-Term Follow-Up 387
Secondary malignancies after treatment for indolent non-Hodgkin's lymphoma: A 16-year follow-up study 355
Second malignancies after treatment of diffuse large B-cell non-Hodgkin's lymphoma: a GISL cohort study 345
Safety and efficacy of lenalidomide in combination with rituximab in recurrent indolent non-follicular lymphoma: Final results of a phase II study conducted by the Fondazione Italiana Linfomi 327
A concise review of lenalidomide therapy for follicular lymphoma 297
The classic prognostic factors in advanced Hodgkin’s lymphoma patients are losing their meaning at the time of Pet-guided treatments 295
Bendamustine, Low-dose dexamethasone, and lenalidomide (BdL) for the treatment of patients with relapsed/refractory multiple myeloma confirms very promising results in a phase I/II study 291
Body composition and inflammation impact in non-small cell lung cancer patients treated by first-line immunotherapy 286
Neutrophil-lymphocyte ratio at diagnosis is an independent prognostic factor in patients with nodular sclerosis Hodgkin lymphoma: Results of a large multicenter study involving 990 patients 273
Risk for second malignancies in non-Hodgkin's lymphoma survivors: a meta-analysis 266
Risk of second primary malignancy in breast cancer survivors: A nested population-based case-control study 263
Survival of multiple myeloma patients in the era of novel therapies confirms the improvement in patients younger than 75 years: a population-based analysis 262
Radiation therapy improves treatment outcome in patients with diffuse large B-cell lymphoma 256
Prognostic models for diffuse large B-cell lymphoma in the rituximab era: a never-ending story. 255
Phase II Study of Velcade (R) Plus Mabthera (R) In Relapsed Follicular Lymphomas. 254
Analysis of Frequency and Risk Factors for Developing Bisphosphonate Associated Osteonecrosis of the Jaw. 246
Incidence and outcome of Myelodysplastic Syndromes in province of Modena 244
Biological effects of Atra and Arsenic Trioxide on short term cultures of non-M3 leukemic blasts 243
BISPHOSPHONATES (BP) RELATED OSTEONECROSIS OF THE JAW (ONJ): A LONG TERM FOLLOW UP (FU) OF A SERIES OF 35 CASES OBSERVED BY GISL 241
Bisphosphonate-associated osteonecrosis of the jaw: a review of 35 cases and an evaluation of its frequency in multiple myeloma patients 239
INCIDENCE AND SURVIVAL OF MYELOID MALIGNANCIES IN 1102 PATIENTS IN PROVINCE OF MODENA, NORTHERN ITALY 237
Incidence and outcome of chronic myeloproliferative disorders: A population-based study from a cancer registry in northern Italy 234
A RANDOMIZED PHASE II STUDY (GISL - MM03 TRIAL) WITH ORAL MELPHALAN+ PREDNISONE (MP) VERSUS MELPHALAN, + PREDNISONE + THALIDOMIDE (MPT) FOR NEWLY DIAGNOSED ELDERLY PATIENTS WITH MULTIPLE MYELOMA 234
Rituximab in combination with fludarabine and cyclophosphamide in the treatment of patients with recurrent follicular lymphoma 233
Efficacy Controls and Long-Term Follow-Up of Patients (Pts) Treated with FC Plus Rituximab for Relapsed Follicular NHL. Session Type: Publication Only 230
A randomized trial with melphalan and prednisone versus melphalan and prednisone plus thalidomide in newly diagnosed multiple myeloma patients not eligible for autologous stem cell transplant 215
: Late toxicity and quality of life (QOL) after treatment for Hodgkin disease (HD): A Gruppo Italiano Studio Linfomi (GISL) cohort study on 223 patients 210
Rituximab (R) in Combination with Fludarabine (F) and Cyclophosphamide (C) in Relapsed Follicular Lymphoma (FL) Patients (pts).Final Results of FC + R Phase II Trial by the GISL. 208
Secondary malignancies after treatment of aggressive non-Hodgkin lymphoma: A GISL cohort study on 1259 patients 205
Bisphosphonates-associated osteonecrosis of the jaw: A long-term follow-up of a series of 35 cases observed by GISL and evaluation of its frequency over time 204
Second Malignancy After Treatment for Non-Hodgkin Lymphoma: a Systematic Review and a Meta-Analysis of Population-Based and Cohort Studies 204
SECOND MALIGNANCIES AFTER TREATMENT FOR INDOLENT LYMPHOMA: A 16 YEARS FOLLOW-UP STUDY 200
VALIDATION OF ABSOLUTE LYMPHOCYTE COUNT / REVISED IPI (ALC/R-IPI) SCORE MODEL, AS A PROGNOSTIC INDEX FOR DIFFUSE LARGE-B-CELL LYMPHOMA IN RITUXIMAB ERA 192
Improving the international prognostic index score using peripheral blood counts: Results of a large multicenter study involving 520 patients with diffuse large B cell lymphoma 177
Cell of origin (COO), BCL2/MYC status and IPI define a group of patients with Diffuse Large B-cell Lymphoma (DLBCL) with poor prognosis in a real-world clinical setting 171
Treatment of patients with recurrent follicular lymphoma with rituximab in combination with fludarabine and cyclophosphamide 164
Rituximab in combination with chemotherapy has improved survival of patients with follicular lymphoma 150
Epidemiologia degli infortuni lavorativi in minori: risultati di una indagine condotta nella città di Modena nel periodo gennaio-giugno 2000. 149
Totale 10.280
Categoria #
all - tutte 36.904
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 36.904


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2020/2021732 0 0 0 0 0 94 81 122 67 114 176 78
2021/2022874 30 86 80 49 24 74 49 50 107 61 156 108
2022/2023854 92 111 60 78 98 118 26 87 93 10 55 26
2023/2024683 24 26 49 63 145 59 146 48 17 16 35 55
2024/20251.761 66 19 42 121 373 276 124 108 195 56 140 241
2025/20261.743 241 144 204 385 586 183 0 0 0 0 0 0
Totale 10.280